Audit: QRS - Magnesium L-Threonate for Health & Longevity

Audit conducted on 09/07/2026 07:54 using AI4L / Opus 4.8

Iterations

Summary

Items	Count
Total	91
Passed	84
Failed	0
N/A	7
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All content (protocol, benefits, risks, contraindications, interactions, monitoring, qualitative markers) traces to the ER.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“Sleep benefits are weaker than marketed” mirrors ER “objective evidence is weaker than the marketing suggests”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	No strengthening/softening; contraindication severity preserved.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications map to ER “Populations who should avoid”; interactions map to ER interactions; benefits/risks retain their ER tiers.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	QRS contains no citations, NCT IDs, expert names, or brand names.
1.6	The QRS does not introduce new attributions.	🟢	No attributions introduced.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, evidence-graded tone consistent with the ER.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Objective and accessible throughout.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents evidence, not directives.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No advisory language; footer disclaims.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Protocol and gates present ER facts.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Plain-language phrasing used; technical terms glossed in the ER context.
2.8	Information is presented in a concise and very compact manner	🟢	Compact cells and lists.
2.9	It DOES NOT address the reader directly	🟢	No “you”/direct address present.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Framing targets proactive, optimization-focused adults.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Protocol/titration/monitoring assume a willing, engaged reader.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Not general-population framed.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Benefit/risk weighting reflects the optimization audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No “anti-aging” language used.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Uses clinical terms (gastrointestinal disturbance, hypermagnesemia, sedation); “grogginess” is carried verbatim from the ER.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed labels/headings present and unmodified.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All expected variable spans present (header, at_a_glance, actions, times, benefits, gates, risks, markers, cadence, qualitative).
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Non-addressed spans unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No QRS-mapped ER section is empty; empty tiers are handled via display:none per 12.5/13.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Benefit/risk tier labels (“Medium”, “Low”, “Speculative”) retained verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Tier and monitoring labels preserved.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji indicators in the QRS.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Content condensed to fit a single page.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Metadata comment is the first element after the doctype (lines 2-14).
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	YAML delimited by “—” (lines 3 and 13).
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; not rendered.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Values trimmed; only “duration” quoted (contains colon).
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: magnesium_l_threonate_2026-0709-0639_Opus_ER.md
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0709-0737
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 4.8
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 4.8” is nickname + version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: magnesium_l_threonate_2026-0709-0639_Opus_QRS.html
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values clean and consistent.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Magnesium L-Threonate for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Magnesium L-Threonate for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0709-0737 → 07/09/2026.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 4.8”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only date, source line, and model.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Distills the Conclusion (lines 415-417).
7.2	[at_a_glance] is no longer than 60 words	🟢	55 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Brain-targeting, cognitive gains, calmer nervous system, weak sleep evidence, and kidney-only serious risk all map to Conclusion passages.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Plain-language wording; no acronyms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial specifics.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No statistics cited.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Sourced from the ER “Populations who should avoid or use only under supervision” (lines 278-282).
8.2	[stop_items] represent the Contraindications from the ER	🟢	Kidney disease, heart-conduction disease, myasthenia gravis, pregnancy/breastfeeding.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Each item is a <li>.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing clauses (e.g., “— absolute caution due to hypermagnesemia risk”) stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	eGFR <30 threshold and heart-block/bradycardia qualifiers preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER contraindications use no severity-ranking notation.
8.7	If no [stop_items] are present the section is left empty	N/A	Contraindications are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Sourced from ER Interactions (lines 256-277).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Antibiotics, bisphosphonates/levothyroxine, gabapentin, diuretics, digoxin, mg antacids/laxatives, PPIs, other mg supplements, calcium/zinc, sedating/hypotensive agents.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Each item is a <li>.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Mechanistic rationale and separation-timing clauses stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug-class parentheticals preserved (tetracyclines/fluoroquinolones; loop/thiazide/potassium-sparing; glycinate/citrate/oxide).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER interactions use no severity-ranking notation.
9.7	If no [caution_items] are present the section is left empty	N/A	Key Interactions are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Dose/timing/titration derived from ER Therapeutic Protocol and dosing guidance.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, Timing, and Titration are the key actionable aspects.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three actionable aspects exist; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All three action cells filled with ER-derived content.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	ER provides two distinct time-to-effect aspects (cognition; calming), both captured.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Cognition (Medium) precedes Calm & stress (Low).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	🟢	Only two aspects exist; the third set is empty and display:none.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Both used time cells filled from ER Practical Considerations (line 349).
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Tiers mirror ER Expected Benefits.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four variables present.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Concise labels; “⚠️ Conflicted” qualifiers dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	“Mood Support (Low Mood & Anxiety)” reduced to “mood support”.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_high (no High tier in ER) set to display:none.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Tiers mirror ER Potential Risks & Side Effects.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four variables present.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Concise labels only.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical detail carried through.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high (no High tier in ER) set to display:none.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table sourced from ER Monitoring (lines 375-381).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All five biomarkers (RBC magnesium, serum magnesium, eGFR/creatinine, ionized magnesium, calcium & vitamin D) listed.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	“Baseline, recheck at ~3 months, then every 6–12 months”.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Sourced from ER qualitative markers (lines 385-389).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five qualitative markers listed verbatim.

Issues 09/07/2026 07:54

Pass rate 100.00%. No issues found.

Issues 09/07/2026 07:47

1. 11.1 / 11.3 — Padded third time-to-effect cell: The ER provides only two distinct time-to-effect aspects — cognition (“4–12 weeks”) and sleep/calming bundled as one statement (“Sleep and calming effects, if present, may be noticed within days”, ER line 349). The QRS splits the single “within days” statement across two cells (Calm & stress, Sleep), so the third set (time_3 “Sleep”, lines 503–513) does not cover a distinct aspect and should have been left empty and invisible.

Fixes 09/07/2026 07:47

1. 11.1 / 11.3 — Padded time-to-effect cell removed: Emptied the third time-to-effect cell (formerly “Sleep” / “Within days”) and set its .pcell to display: none, leaving only the two distinct aspects the ER supports — Cognition (4–12 weeks) and Calm & stress (Within days).